Business
Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
GAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ -- NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the
About this update from Novavax, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ -- \nNVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union, Australia, Canada, and Great Britain; authorizations granted by 12 regulatory agencies and emergency use listing from the WHO Additional filings for authorization under review, including in the United States Initiated vaccine shipments globally, with doses administered in the European Union, Australia, Indonesia and South Korea Expanded clinical body of evidence for NVX-CoV2373 across several studies, including: 82.5% overall protection against all COVID-19 infection in extended analysis of UK Phase 3 study 82% efficacy against Delta variant in PREVENT-19 pediatric expansion for adolescents aged 12 through 17 Broad cross-reactivity against Omicron and other variants following a 2-dose primary series, with increased immune responses after 6-month booster doseDeveloped Omicron-specific vaccine; GMP manufacturing ongoing with delivery expected toward the end of first quarter of 2022 Full year 2022 total revenue guidance of between $4 billion and $5 billion Company to host conference call today at 4:30 p.m. ETNovavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2021.\n\"NVX-CoV2373 has now received regulatory authorizations globally, representing the potential to reach more than six billion lives. We are now delivering our vaccine around the world, with immunizations already happening in the European Union, Asia and Australia to meet the continued need to achieve high vaccination rates through primary immunization, boosting and protection of pediatric age groups,\" said Stanley C. Erck, President and Chief Executive Officer, Novavax. \"We also remain focused on expanding access to our vaccine through additional regulatory filings and ongoing research to add to our robust body of clinical data. We are confident in NVX-CoV2373's potential as a vital vaccine option due to its reassuring safety profile and demonstrated efficacy against variants with the benefits of refrigerator-stable storage.\"\nFourth Quarter 2021 and Rece...